Global Big Pharma Partnering Terms and Agreements 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Apr-2017
No. of pages: 1000
Inquire Before Buying

Summary

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals

Global Big Pharma Partnering Terms and Agreements 2010 to 2017 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Big Pharma agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 3,000 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Big Pharma deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2010. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

Key benefits

Global Big Pharma Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Big Pharma deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of Big Pharma agreements with real life case studies

Detailed access to actual Big Pharma contracts entered into by leading biopharma companies

Identify most active Big Pharma dealmakers since 2010

Insight into terms included in a Big Pharma partnering agreement, with real world examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Big Pharma Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Big Pharma trends and structure of deals entered into by leading companies worldwide.

Big Pharma Partnering Terms and Agreements includes:

Trends in Big Pharma dealmaking in the biopharma industry since 2010

Analysis of Big Pharma deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life Big Pharma deals

Access to Big Pharma contract documents

Leading Big Pharma deals by value since 2010

Most active Big Pharma dealmakers since 2010

In Global Big Pharma Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Big Pharma Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 3,000 Big Pharma deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Big Pharma Partnering Terms and Agreements 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Big Pharma dealmaking

2.1. Introduction
2.2. Big Pharma partnering over the years
2.3. Most active Big Pharma dealmakers
2.4. Big Pharma partnering by deal type
2.5. Big Pharma partnering by therapy area
2.6. Big Pharma partnering by technology type
2.7. Deal terms for Big Pharma partnering
2.7.1 Big Pharma partnering headline values
2.7.2 Big Pharma deal upfront payments
2.7.3 Big Pharma deal milestone payments
2.7.4 Big Pharma royalty rates

Chapter 3 - Leading Big Pharma deals

3.1. Introduction
3.2. Top Big Pharma deals by value

Chapter 4 - Most active Big Pharma dealmakers

4.1. Introduction
4.2. Most active Big Pharma dealmakers
4.3. Most active Big Pharma partnering company profiles
Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others

Chapter 5 - Big Pharma contracts dealmaking directory

5.1. Introduction
5.2. Big Pharma contracts dealmaking directory

Chapter 6 - Big Pharma dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Big Pharma deals by company A-Z
Appendix 2 - Big Pharma deals by stage of development
Appendix 3 - Big Pharma deals by deal type
Appendix 4 - Big Pharma deals by therapy area
Appendix 5 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Big Pharma partnering since 2010
Figure 2: Active Big Pharma dealmaking activity since 2017
Figure 3: Big Pharma partnering by deal type since 2010
Figure 4: Big Pharma partnering by disease type since 2010
Figure 5: Big Pharma partnering by technology type since 2010
Figure 6: Big Pharma deals with a headline value
Figure 7: Big Pharma deals with an upfront value
Figure 8: Big Pharma deals with a milestone value
Figure 9: Big Pharma deals with a royalty rate value
Figure 10: Top Big Pharma deals by value since 2010
Figure 11: Most active Big Pharma dealmakers since 2017
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 […]
  • Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2016
    Published: 01-Apr-2017        Price: US 1500 Onwards        Pages: 111
    Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2016 Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2016", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt o......
  • Global Pharmerging Contract Manufacturings Market Size, Status and Forecast 2022
    Published: 09-Mar-2017        Price: US 3300 Onwards        Pages: 99
    This report studies the global Pharmerging Contract Manufacturings market, analyzes and researches the Pharmerging Contract Manufacturings development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Cipla - Piramal Healthcare - Aurobindo - Jubilant Life Sciences - Zydus Cadila - Alkem - Intas - Lupin - Torrent - FDC ......
  • Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals
    Published: 07-Mar-2017        Price: US 1000 Onwards        Pages: 85
    Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, ......
  • Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
    Published: 01-Mar-2017        Price: US 2995 Onwards        Pages: 1000
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies. The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides details of the......
  • CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan
    Published: 13-Feb-2017        Price: US 1995 Onwards        Pages: 200
    CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan Summary Pharmaceutical market in Japan is set to rise from around $70 billion in 2016 to $72 billion by 2021, representing a low compound annual growth rate of 0.3%. Although increasing generic substitution and yearly pricing reviews are likely to restrict growth in the Japanese pharmaceutical market in the future, the government is also working to reduce long regulatory processes face......
  • Partnerships, Licensing, Investments and M&A Deals and Trends for December 2016 in Pharmaceuticals
    Published: 10-Feb-2017        Price: US 1000 Onwards        Pages: 89
    Partnerships, Licensing, Investments and M&A Deals and Trends for December 2016 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for December 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As......
  • CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia
    Published: 09-Feb-2017        Price: US 1995 Onwards        Pages: 200
    CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia Summary Pharmaceutical market in Russia is one of the fastest growing globally and is set to rise from $20.91 billion in 2016 to $38.56 billion by 2021, representing a compound annual growth rate (CAGR) of 13%. For pharmaceutical companies hoping to profit from the Russian market in coming years, the country's increasing focus on biotechnology may provide ample opportunity. In 2012, the government......
  • CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France
    Published: 07-Feb-2017        Price: US 1995 Onwards        Pages: 234
    CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France Summary Pharmaceuticals market in France is set to decline from $35.5 billion in 2017 to $34.16 billion in 2021, representing a negative compound annual growth rate of 1%. Despite France's robust public health insurance system and rising elderly population, increasing pressure on pharmaceutical selling prices, patent expiration of branded drugs and foreign exchange fluctuations are st......
  • Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2017
    Published: 01-Feb-2017        Price: US 2995 Onwards        Pages: 481
    Summary The Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. Description The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides co......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs